Unanswered Question Answered: GLP-1 RA for Primary Prevention in Low Risk CV Patients with Diabetes

Classes Diabetes Unanswered Question Answered: GLP-1 RA for Primary Prevention in Low Risk CV Patients with Diabetes

Instructions

Please Sign in to your account to see the Class.

Introduction

In this short video, Dr. Esteban Jodar Gimeno discusses the outcomes of the REWIND study and explains the beneficial effects of dulaglutide for primary prevention in a low CV risk T2D population.